Table 3. Analysis of associations between the HSPA8 polymorphisms and risk of CHD.

	Cases		Controls		Crude OR (95% CI)	Adjusted OR (95% CI)*
Genotype	N	(%)	N	(%)
rs1461496
GG	321	33.3	341	34.4	1.00	1.00
AG	435	45.1	464	46.9	1.00(0.82, 1.22)	1.01(0.79, 1.29)
AA	209	21.7	185	18.7	1.20(0.94, 1.54)	1.19(0.88, 1.62)
AG+AA	644	66.8	649	65.6	1.05(0.87,1.27)	1.06(0.84, 1.34)
rs10892958
GG	336	34.6	305	30.7	1.00	1.00
GC	453	46.7	495	49.8	0.83(0.68, 1.02)	0.79(0.62, 1.02)
CC	181	18.7	194	19.5	0.85(0.66, 1.09)	0.82(0.60, 1.13)
GC+CC	634	65.4	689	69.3	0.84(0.69, 1.01)	0.80(0.64, 1.01)
rs2276077
GG	721	74.6	749	75.5	1.00	1.00
AG	228	23.6	228	23.0	1.04(0.84, 1.28)	0.99(0.76, 1.28)
AA	18	1.9	15	1.5	1.25(0.62, 2.49)	2.00(0.81, 4.99)
AG+AA	246	25.5	243	24.5	1.05(0.86,1.29)	1.03(0.81,1.33)
rs2236659
TT	652	68.0	624	63.7	1.00	1.00
CT	267	27.8	313	32.0	0.82(0.67, 0.99) †	0.76(0.59, 0.97) ‡
CC	40	4.2	42	4.3	0.91(0.58, 1.43)	0.93(0.54, 1.61)
CT+CC	307	32.0	355	36.3	0.83(0.69, 1.00) §	0.78(0.62, 0.98) ||

*Adjusted for age, sex, pack-years of smoking, drinking, activity, hypertension, diabetes milletus and family history of CHD.

†P = 0.043, ‡ P = 0.025, § P = 0.049, and ||P = 0.033 respectively when compared with TT genotype of rs2236659.